Previous 10 | Next 10 |
Today, we take our first in-depth look at a medical cosmetology company named Evolus. The company's rollout of Botox competitor Jeuveau has been hampered by impacts from the pandemic as well as litigation. A full investment analysis follows in the paragraphs below. For furth...
Gainers: VYNE Therapeutics (VYNE) +33%, Evolus (EOLS) +33%, Accelerate Diagnostics (AXDX) +32%, Atossa Therapeutics (ATOS) +29%, Bionano Genomics (BNGO) +27%.Losers: Neuronetics (STIM) -14%, Akerna (KERN) -10%, Precigen (PGEN) -9%,...
Evolus (EOLS) is trading 5.9% higher in apparent reaction to yesterday’s agreement between Allergan Aesthetics of AbbVie (ABBV) and Cypris Medical following which Allergan will have an option to acquire the Chicago-based medical device company.Evolus is a performanc...
Evolus ([[EOLS]] +2.8%) and Oxford Finance have entered into a letter agreement pursuant to which Evolus paid Oxford $76M as "Payoff Amount” to discharge in full all outstanding obligations under a Loan and Security Agreement, dated March 15, 2019.As a result of entering into...
Gainers: Vivos Therapeutics (VVOS) +51%, Jupiter Wellness (JUPW) +21%, Evolus (EOLS) +27%, PainReform (PRFX) +24%, Rite Aid (RAD) +23%.Losers: BioCardia (BCDA) -23%, SCYNEXIS (SCYX) -19%, Zynerba Pharmaceuticals (ZYNE) -15%, Han...
Takung Art (TKAT) +81%.Evolus (EOLS) +43% after company updates on U.S. ITC case related to Jeuveau sales and marketing.Skillful Craftsman Education Technology (EDTK) +17%.Marathon Patent Group (MARA) +23%.Rite Aid Corporation (RAD) +21% on Q3 results.Vivos Therapeuti...
Gainers: [[SCPS]] +27.7%. [[EOLS]] +23.2%. [[GTAT]] +21.8%. [[MGNX]] +15.7%. [[SELB]] +10.3%.Losers: [[SCYX]] -15.8%. [[QTT]] -9.2%. [[APEN]] -6.8%. [[TRITW]] -6.7%. [[ETM]] -4.3%. For further details see: SCPS, EOLS, SCYX and QTT among after-hours movers
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Evolus To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 6, 2020) - If you suffered losses exceeding $100,000 investing in Evolus stock or o...
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Evolus To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 4, 2020) - If you suffered losses exceeding $100,000 investing in Evolus stock or o...
The company is awaiting a decision from the ITC concerning the use of Jeuveau in the US. Implied volatility is well over 240%. The stock is dirt-cheap if the ban is not inflicted. Risk is high, however, so we are leaning towards a volatility play instead of a directional one. ...
News, Short Squeeze, Breakout and More Instantly...
Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End Improved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Qua...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast. The even...
Launching into this growth market 1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ: EOLS), a perf...